|
|
|
|
|
|
|
|
|
26.08.26 - 08:51
|
BioArctic: Interim Report for the period April - June 2026 (PR Newswire)
|
|
|
New approvals for Leqembi® and additional strategic partnerships STOCKHOLM, Aug. 26, 2026 /PRNewswire/ -- Events during the second quarter 2026 Eisai provided a sales forecast for Leqembi for the company's fiscal year 2026 (April 2026 to March 2027) of a total of JPY 143.5 billion......
|
|
|
26.08.26 - 08:45
|
BioArctic: Interim Report for the period April - June 2026 (PR Newswire)
|
|
|
New approvals for Leqembi® and additional strategic partnerships STOCKHOLM, Aug. 26, 2026 /PRNewswire/ -- Events during the second quarter 2026 Eisai provided a sales forecast for Leqembi for the company's fiscal year 2026 (April 2026 to March 2027) of a total of JPY 143.5 billion......
|
|
|
26.08.26 - 08:00
|
Interim Report for the period April – June 2026 (Cision)
|
|
|
New approvals for Leqembi[®] and additional strategic partnerships
Events during the second quarter 2026
· Eisai provided a sales forecast for Leqembi for the company's fiscal year 2026 (April 2026 to March 2027) of a total of JPY 143.5 billion (approximately SEK 8.4 billion), corresponding to 63% growth compared with the previous year
· BioArctic entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic's proprietary BrainTransporter™-technology with an undisclosed drug candidate from Eli Lilly...
|
|
|
24.08.26 - 14:48
|
Leqembi Iqlik® for initiation treatment launched in the US (PR Newswire)
|
|
|
STOCKHOLM, Aug. 24, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced that lecanemab-irmb subcutaneous injection (US brand name: Leqembi Iqlik®), which was approved by the FDA on July 13, now is available in the US for initiation therapy......
|
|
|
|
|
24.08.26 - 14:42
|
Leqembi Iqlik® for initiation treatment launched in the US (PR Newswire)
|
|
|
STOCKHOLM, Aug. 24, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced that lecanemab-irmb subcutaneous injection (US brand name: Leqembi Iqlik®), which was approved by the FDA on July 13, now is available in the US for initiation therapy......
|
|
|
|
|
|
|
|
|
|
|
|
|
03.08.26 - 09:24
|
Eisai Q1 Net Income Rises (AFX)
|
|
|
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Eisai Co. (4523.T, EII.SG) reported that its first-quarter profit attributable to owners of the parent increased 26.0% to 18.24 billion yen from 14.47 billion ......
|
|
|
|
|
|
|
29.07.26 - 10:48
|
Eisai and CORE Biomedicine agree on global licence for oncology pipeline (PBR)
|
|
|
The deal grants CORE Biomedicine rights to develop and commercialise a portfolio of cancer therapies originally discovered by Eisai and its affiliates. The licensed assets focus on targeting
The post Eisai and CORE Biomedicine agree on global licence for oncology pipeline appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
